Quidel Corp (QDEL) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
February 12, 2020 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and the year ended December 31, 2019.
Fourth Quarter 2019 Highlights
Total revenue increased 15% to $152.2 million, compared with $132.6 million in the fourth quarter of 2018. Cardiac Immunoassay revenue increased 5% to $65.8 million. Molecular Diagnostic Solutions revenue was $7.1 million, 21% growth from the fourth quarter of 2018. Influenza revenue increased 44% to $50.3 million, compared with $34.9 million in the fourth quarter of... More